These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25229924)

  • 21. Oritavancin (Orbactiv) for skin and skin structure infections.
    Med Lett Drugs Ther; 2015 Jan; 57(1459):3-5. PubMed ID: 25555072
    [No Abstract]   [Full Text] [Related]  

  • 22. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
    Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
    Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalbavancin: a review for dermatologists.
    Scheinfeld N
    Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dalbavancin (Dalvance) for the treatment of acute bacterial skin infection.
    Gupta AK; Foley KA; Abramovits W; Rosen T
    Skinmed; 2014; 12(6):366-9. PubMed ID: 25823083
    [No Abstract]   [Full Text] [Related]  

  • 25. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies.
    Dunne MW; Sahm D; Puttagunta S
    Ann Clin Microbiol Antimicrob; 2015 Apr; 14():19. PubMed ID: 25885674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections.
    Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
    Nurse Pract; 2018 Oct; 43(10):31-37. PubMed ID: 30153191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab.
    Hussar DA; Nguyen A
    J Am Pharm Assoc (2003); 2014; 54(6):658-62. PubMed ID: 25379985
    [No Abstract]   [Full Text] [Related]  

  • 28. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy.
    Van Bambeke F
    Curr Opin Investig Drugs; 2006 Aug; 7(8):740-9. PubMed ID: 16955686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dalbavancin approved for acute skin infections.
    Traynor K
    Am J Health Syst Pharm; 2014 Jul; 71(13):1062. PubMed ID: 24939490
    [No Abstract]   [Full Text] [Related]  

  • 31. Dalbavancin: a review.
    Scheinfeld N
    Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing acute bacterial skin and skin structure infections: Focus on new lipoglycopeptides.
    Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
    Nurse Pract; 2017 May; 42(5):1-6. PubMed ID: 28406838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.
    Henson KE; Levine MT; Wong EA; Levine DP
    Expert Rev Anti Infect Ther; 2015; 13(10):1265-78. PubMed ID: 26165756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
    J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Origin, structure, and activity in vitro and in vivo of dalbavancin.
    Malabarba A; Goldstein BP
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii15-20. PubMed ID: 15750032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
    Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S
    Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections.
    Dunne MW; Zhou M; Darpo B
    Int J Antimicrob Agents; 2015 Apr; 45(4):393-8. PubMed ID: 25681068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.